Prognostic value of measurable residual disease (MRD) for venetoclax in combination with hypomethylating agents in patients diagnosed with acute myeloid leukemia: validation of the ELN-2021 MRD recommendations
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2025-05-01
|
| Series: | Blood Cancer Journal |
| Online Access: | https://doi.org/10.1038/s41408-025-01298-6 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849726046871486464 |
|---|---|
| author | Carlos Jimenez-Vicente Aina Cardus Sandra Castaño-Diez Guillermo Ramil Sara Garcia-Avila Lucia Gomez-Perez Daniel Esteban Iago Arribas Antonella Lucia Sturla Monica Lopez-Guerra Alexandra Martinez-Roca Albert Cortes-Bullich Amanda Isabel Perez-Valencia Ines Zugasti Ines Monge Esther Carcelero Ferran Vall-Llovera Susana Vives Jorge Sierra Josep Nomdedeu Guadalupe Oñate Ana Garrido Marta Pratcorona Helena Pomares Montserrat Arnan Francesca Guijarro Marina Diaz-Beya Jordi Esteve on behalf of the Spanish CETLAM Group |
| author_facet | Carlos Jimenez-Vicente Aina Cardus Sandra Castaño-Diez Guillermo Ramil Sara Garcia-Avila Lucia Gomez-Perez Daniel Esteban Iago Arribas Antonella Lucia Sturla Monica Lopez-Guerra Alexandra Martinez-Roca Albert Cortes-Bullich Amanda Isabel Perez-Valencia Ines Zugasti Ines Monge Esther Carcelero Ferran Vall-Llovera Susana Vives Jorge Sierra Josep Nomdedeu Guadalupe Oñate Ana Garrido Marta Pratcorona Helena Pomares Montserrat Arnan Francesca Guijarro Marina Diaz-Beya Jordi Esteve on behalf of the Spanish CETLAM Group |
| author_sort | Carlos Jimenez-Vicente |
| collection | DOAJ |
| format | Article |
| id | doaj-art-9dd2a1e2f17a4133ae7251d9372e26d2 |
| institution | DOAJ |
| issn | 2044-5385 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Nature Publishing Group |
| record_format | Article |
| series | Blood Cancer Journal |
| spelling | doaj-art-9dd2a1e2f17a4133ae7251d9372e26d22025-08-20T03:10:18ZengNature Publishing GroupBlood Cancer Journal2044-53852025-05-011511510.1038/s41408-025-01298-6Prognostic value of measurable residual disease (MRD) for venetoclax in combination with hypomethylating agents in patients diagnosed with acute myeloid leukemia: validation of the ELN-2021 MRD recommendationsCarlos Jimenez-Vicente0Aina Cardus1Sandra Castaño-Diez2Guillermo Ramil3Sara Garcia-Avila4Lucia Gomez-Perez5Daniel Esteban6Iago Arribas7Antonella Lucia Sturla8Monica Lopez-Guerra9Alexandra Martinez-Roca10Albert Cortes-Bullich11Amanda Isabel Perez-Valencia12Ines Zugasti13Ines Monge14Esther Carcelero15Ferran Vall-Llovera16Susana Vives17Jorge Sierra18Josep Nomdedeu19Guadalupe Oñate20Ana Garrido21Marta Pratcorona22Helena Pomares23Montserrat Arnan24Francesca Guijarro25Marina Diaz-Beya26Jordi Esteve27on behalf of the Spanish CETLAM GroupHematology Department. Hospital Clínic de BarcelonaInstitut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)Hematology Department. Hospital Clínic de BarcelonaHematology Department. Hospital de la Santa Creu i Sant Pau. Universitat Autònoma de Barcelona and IIB Sant PauHematology Department. Hospital del Mar, Barcelona, España. Hospital del Mar Research InstituteHematology Department. Hospital del Mar, Barcelona, España. Hospital del Mar Research InstituteHematology Department. ICO-Hospital Universitari Germans Trias i Pujol, Institut de Recerca Josep Carreras. Badalona. Universitat Autònoma de BarcelonaHematology Department, Institut Català d’Oncologia - Hospital Duran I Reynals; Institut d’Investigació Biomèdica de Bellvitge (IDIBELL), Universitat de BarcelonaHematology Department, Institut Català d’Oncologia - Hospital Duran I Reynals; Institut d’Investigació Biomèdica de Bellvitge (IDIBELL), Universitat de BarcelonaInstitut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)Hematology Department. Hospital Clínic de BarcelonaHematology Department. Hospital Clínic de BarcelonaHematology Department. Hospital Clínic de BarcelonaHematology Department. Hospital Clínic de BarcelonaPharmacy Department, Hospital Clínic de BarcelonaPharmacy Department, Hospital Clínic de BarcelonaHospital Universitari Mutua Terrassa, TerrassaHematology Department. ICO-Hospital Universitari Germans Trias i Pujol, Institut de Recerca Josep Carreras. Badalona. Universitat Autònoma de BarcelonaHematology Department. Hospital de la Santa Creu i Sant Pau. Universitat Autònoma de Barcelona and IIB Sant PauHematology Department. Hospital de la Santa Creu i Sant Pau. Universitat Autònoma de Barcelona and IIB Sant PauHematology Department. Hospital de la Santa Creu i Sant Pau. Universitat Autònoma de Barcelona and IIB Sant PauHematology Department. Hospital de la Santa Creu i Sant Pau. Universitat Autònoma de Barcelona and IIB Sant PauHematology Department. Hospital de la Santa Creu i Sant Pau. Universitat Autònoma de Barcelona and IIB Sant PauHematology Department, Institut Català d’Oncologia - Hospital Duran I Reynals; Institut d’Investigació Biomèdica de Bellvitge (IDIBELL), Universitat de BarcelonaHematology Department, Institut Català d’Oncologia - Hospital Duran I Reynals; Institut d’Investigació Biomèdica de Bellvitge (IDIBELL), Universitat de BarcelonaInstitut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)Hematology Department. Hospital Clínic de BarcelonaHematology Department. Hospital Clínic de Barcelonahttps://doi.org/10.1038/s41408-025-01298-6 |
| spellingShingle | Carlos Jimenez-Vicente Aina Cardus Sandra Castaño-Diez Guillermo Ramil Sara Garcia-Avila Lucia Gomez-Perez Daniel Esteban Iago Arribas Antonella Lucia Sturla Monica Lopez-Guerra Alexandra Martinez-Roca Albert Cortes-Bullich Amanda Isabel Perez-Valencia Ines Zugasti Ines Monge Esther Carcelero Ferran Vall-Llovera Susana Vives Jorge Sierra Josep Nomdedeu Guadalupe Oñate Ana Garrido Marta Pratcorona Helena Pomares Montserrat Arnan Francesca Guijarro Marina Diaz-Beya Jordi Esteve on behalf of the Spanish CETLAM Group Prognostic value of measurable residual disease (MRD) for venetoclax in combination with hypomethylating agents in patients diagnosed with acute myeloid leukemia: validation of the ELN-2021 MRD recommendations Blood Cancer Journal |
| title | Prognostic value of measurable residual disease (MRD) for venetoclax in combination with hypomethylating agents in patients diagnosed with acute myeloid leukemia: validation of the ELN-2021 MRD recommendations |
| title_full | Prognostic value of measurable residual disease (MRD) for venetoclax in combination with hypomethylating agents in patients diagnosed with acute myeloid leukemia: validation of the ELN-2021 MRD recommendations |
| title_fullStr | Prognostic value of measurable residual disease (MRD) for venetoclax in combination with hypomethylating agents in patients diagnosed with acute myeloid leukemia: validation of the ELN-2021 MRD recommendations |
| title_full_unstemmed | Prognostic value of measurable residual disease (MRD) for venetoclax in combination with hypomethylating agents in patients diagnosed with acute myeloid leukemia: validation of the ELN-2021 MRD recommendations |
| title_short | Prognostic value of measurable residual disease (MRD) for venetoclax in combination with hypomethylating agents in patients diagnosed with acute myeloid leukemia: validation of the ELN-2021 MRD recommendations |
| title_sort | prognostic value of measurable residual disease mrd for venetoclax in combination with hypomethylating agents in patients diagnosed with acute myeloid leukemia validation of the eln 2021 mrd recommendations |
| url | https://doi.org/10.1038/s41408-025-01298-6 |
| work_keys_str_mv | AT carlosjimenezvicente prognosticvalueofmeasurableresidualdiseasemrdforvenetoclaxincombinationwithhypomethylatingagentsinpatientsdiagnosedwithacutemyeloidleukemiavalidationoftheeln2021mrdrecommendations AT ainacardus prognosticvalueofmeasurableresidualdiseasemrdforvenetoclaxincombinationwithhypomethylatingagentsinpatientsdiagnosedwithacutemyeloidleukemiavalidationoftheeln2021mrdrecommendations AT sandracastanodiez prognosticvalueofmeasurableresidualdiseasemrdforvenetoclaxincombinationwithhypomethylatingagentsinpatientsdiagnosedwithacutemyeloidleukemiavalidationoftheeln2021mrdrecommendations AT guillermoramil prognosticvalueofmeasurableresidualdiseasemrdforvenetoclaxincombinationwithhypomethylatingagentsinpatientsdiagnosedwithacutemyeloidleukemiavalidationoftheeln2021mrdrecommendations AT saragarciaavila prognosticvalueofmeasurableresidualdiseasemrdforvenetoclaxincombinationwithhypomethylatingagentsinpatientsdiagnosedwithacutemyeloidleukemiavalidationoftheeln2021mrdrecommendations AT luciagomezperez prognosticvalueofmeasurableresidualdiseasemrdforvenetoclaxincombinationwithhypomethylatingagentsinpatientsdiagnosedwithacutemyeloidleukemiavalidationoftheeln2021mrdrecommendations AT danielesteban prognosticvalueofmeasurableresidualdiseasemrdforvenetoclaxincombinationwithhypomethylatingagentsinpatientsdiagnosedwithacutemyeloidleukemiavalidationoftheeln2021mrdrecommendations AT iagoarribas prognosticvalueofmeasurableresidualdiseasemrdforvenetoclaxincombinationwithhypomethylatingagentsinpatientsdiagnosedwithacutemyeloidleukemiavalidationoftheeln2021mrdrecommendations AT antonellaluciasturla prognosticvalueofmeasurableresidualdiseasemrdforvenetoclaxincombinationwithhypomethylatingagentsinpatientsdiagnosedwithacutemyeloidleukemiavalidationoftheeln2021mrdrecommendations AT monicalopezguerra prognosticvalueofmeasurableresidualdiseasemrdforvenetoclaxincombinationwithhypomethylatingagentsinpatientsdiagnosedwithacutemyeloidleukemiavalidationoftheeln2021mrdrecommendations AT alexandramartinezroca prognosticvalueofmeasurableresidualdiseasemrdforvenetoclaxincombinationwithhypomethylatingagentsinpatientsdiagnosedwithacutemyeloidleukemiavalidationoftheeln2021mrdrecommendations AT albertcortesbullich prognosticvalueofmeasurableresidualdiseasemrdforvenetoclaxincombinationwithhypomethylatingagentsinpatientsdiagnosedwithacutemyeloidleukemiavalidationoftheeln2021mrdrecommendations AT amandaisabelperezvalencia prognosticvalueofmeasurableresidualdiseasemrdforvenetoclaxincombinationwithhypomethylatingagentsinpatientsdiagnosedwithacutemyeloidleukemiavalidationoftheeln2021mrdrecommendations AT ineszugasti prognosticvalueofmeasurableresidualdiseasemrdforvenetoclaxincombinationwithhypomethylatingagentsinpatientsdiagnosedwithacutemyeloidleukemiavalidationoftheeln2021mrdrecommendations AT inesmonge prognosticvalueofmeasurableresidualdiseasemrdforvenetoclaxincombinationwithhypomethylatingagentsinpatientsdiagnosedwithacutemyeloidleukemiavalidationoftheeln2021mrdrecommendations AT esthercarcelero prognosticvalueofmeasurableresidualdiseasemrdforvenetoclaxincombinationwithhypomethylatingagentsinpatientsdiagnosedwithacutemyeloidleukemiavalidationoftheeln2021mrdrecommendations AT ferranvallllovera prognosticvalueofmeasurableresidualdiseasemrdforvenetoclaxincombinationwithhypomethylatingagentsinpatientsdiagnosedwithacutemyeloidleukemiavalidationoftheeln2021mrdrecommendations AT susanavives prognosticvalueofmeasurableresidualdiseasemrdforvenetoclaxincombinationwithhypomethylatingagentsinpatientsdiagnosedwithacutemyeloidleukemiavalidationoftheeln2021mrdrecommendations AT jorgesierra prognosticvalueofmeasurableresidualdiseasemrdforvenetoclaxincombinationwithhypomethylatingagentsinpatientsdiagnosedwithacutemyeloidleukemiavalidationoftheeln2021mrdrecommendations AT josepnomdedeu prognosticvalueofmeasurableresidualdiseasemrdforvenetoclaxincombinationwithhypomethylatingagentsinpatientsdiagnosedwithacutemyeloidleukemiavalidationoftheeln2021mrdrecommendations AT guadalupeonate prognosticvalueofmeasurableresidualdiseasemrdforvenetoclaxincombinationwithhypomethylatingagentsinpatientsdiagnosedwithacutemyeloidleukemiavalidationoftheeln2021mrdrecommendations AT anagarrido prognosticvalueofmeasurableresidualdiseasemrdforvenetoclaxincombinationwithhypomethylatingagentsinpatientsdiagnosedwithacutemyeloidleukemiavalidationoftheeln2021mrdrecommendations AT martapratcorona prognosticvalueofmeasurableresidualdiseasemrdforvenetoclaxincombinationwithhypomethylatingagentsinpatientsdiagnosedwithacutemyeloidleukemiavalidationoftheeln2021mrdrecommendations AT helenapomares prognosticvalueofmeasurableresidualdiseasemrdforvenetoclaxincombinationwithhypomethylatingagentsinpatientsdiagnosedwithacutemyeloidleukemiavalidationoftheeln2021mrdrecommendations AT montserratarnan prognosticvalueofmeasurableresidualdiseasemrdforvenetoclaxincombinationwithhypomethylatingagentsinpatientsdiagnosedwithacutemyeloidleukemiavalidationoftheeln2021mrdrecommendations AT francescaguijarro prognosticvalueofmeasurableresidualdiseasemrdforvenetoclaxincombinationwithhypomethylatingagentsinpatientsdiagnosedwithacutemyeloidleukemiavalidationoftheeln2021mrdrecommendations AT marinadiazbeya prognosticvalueofmeasurableresidualdiseasemrdforvenetoclaxincombinationwithhypomethylatingagentsinpatientsdiagnosedwithacutemyeloidleukemiavalidationoftheeln2021mrdrecommendations AT jordiesteve prognosticvalueofmeasurableresidualdiseasemrdforvenetoclaxincombinationwithhypomethylatingagentsinpatientsdiagnosedwithacutemyeloidleukemiavalidationoftheeln2021mrdrecommendations AT onbehalfofthespanishcetlamgroup prognosticvalueofmeasurableresidualdiseasemrdforvenetoclaxincombinationwithhypomethylatingagentsinpatientsdiagnosedwithacutemyeloidleukemiavalidationoftheeln2021mrdrecommendations |